Deal facts
- Buyer
- Lixte Biotechnology Holdings, Inc.
- Target
- Nomad Transportable Power Systems, Inc.
- Deal value
- Not disclosed
- Announced
- 2 July 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares, cash
Sources
Lixte Biotechnology Holdings, Inc. has agreed to acquire Nomad Transportable Power Systems, Inc. in a strategic acquisition within the Healthcare sector. The transaction involves a mixed consideration structure comprising both shares and cash, though the specific deal value remains undisclosed. Both the acquiring entity and the target are based in the United States, indicating a domestic consolidation of assets within the same national market. The deal was announced on 2 July 2026, with the transaction officially completing on the preceding day, 1 July 2026. This timeline suggests a rapid execution process where the legal completion preceded the public announcement by a single day. The high confidence ratings attached to the parties and the sector classification confirm the accuracy of these details. The transaction is now considered fully completed and no longer subject to pending regulatory conditions.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Lixte Biotechnology Holdings, Inc. completes acquisition of Nomad Transportable Power Systems, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On June 11, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Nomad Transportable Power Systems, Inc (“NOMAD”) and NBD Merger Sub, Inc., (“Merger Sub”), entered into a Merger Agreement (the “Merger Agreement”), pursuant to which Merger Sub is to be merged with and into NOMAD, with NOMAD surviving as a wholly-owned subsidiary of the Com
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
Lixte Biotechnology Holdings, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive